Checkvacc Clinical Trial - now listed at City of Hope, page-75

looks like COH submitted an abstract for a presentation at the upcoming ISSPP in Rome, Italy from OCt 7-8, 2021.



15:25 Intraperitoneal oncolytic virus for peritoneal metastases
Yanghee Woo (Los Angeles, USA)

THE ROLE OF ONCOLYTIC VIRUSES IN INTRAPERITONEAL THERAPY

Authors: Yanghee Woo, MD; Shyambabu Chaurasiya, PhD; Zhifang Zhang, PhD; Annie Yang, MD; and Yuman Fong

Institution: City of Hope, Duarte, CA, USA

Oncolytic viral therapy is promising field of anticancer immunotherapy. Immuno-oncolytic viruses (IOVs) possess inherent selective cancer killing and the genetically modified capacity to deliver desired human transgenes such as hNIS and antiPDL1. This versatility allows for tumor tracking and enhancing antitumor immunity. We have created a novel IOV platform, CF33 and investigated its potential to treat GI PM. CF33 is an artificially created replication-competent chimeric orthopoxvirus with a large DNA genome. Genetically modified variants, CF33-hNIS and CF33-hNIS-antiPDL1 exhibited a large therapeutic window starting at doses orders of magnitudes lower than those required by other oncolytic viruses (OVs) and the capacity to decrease tumor burden and improve survival. In an aggressively fatal PDAC PM nude mouse model with a subcutaneous (SQ) and peritoneal tumors, various routes (IV, IP, intrathecal [IT]) of CF33-hNIS-antiPDL1 administration resulted in the most robust peritoneal tumor kill with IT injection of SQ tumor (data not published) and least effectiveness with IV. We confirmed that CF33-hNIS-antiPDL1 can not only track and kill peritoneal tumors, but express functional hNIS for imaging of PM and locally deliver antiPDL1. Finally, studies of tumor immunogenicity have revealed that CF33-IOVs alter the immune tumor microenvironment including upregulation of PD-L1 for potential synergistic antitumor immunity. In summary, CF33-IOV-platform demonstrates promising preclinical results against PM.

Abstract GC-01